Complication that occurs in patients to heberprot-p treatment in a health area

Authors

  • Perla María Trujillo Pedrosa Policlínico “Manuel Piti Fajardo”, Santo Domingo, Villa Clara
  • Maité George Arse Policlínico “Manuel Piti Fajardo”, Santo Domingo, Villa Clara
  • Justo Ricardo Ortega Sánchez Policlínico “Manuel Piti Fajardo”, Santo Domingo, Villa Clara

Keywords:

diabetes mellitus, heberprot-p, sepsis, risk factor

Abstract

Introduction: diabetes is considered an epidemic in the world. Diabetic foot is a serious health problem in Cuba. Heberprot-p is a novel drug that can solve a medical need not covered worldwide. Objective: to determine the complication that occurred during therapy with heberprot-p. Method: a descriptive longitudinal study was performed in 108 patients treated with heberprot-p in “Manuel Piti Fajardo” Policlinic in Santo Domingo between January 2012 and December 2015, the sample consisted of 14 patients who had a non-satisfactory evolution. The information was obtained by the survey method and through the review of medical records and treatment registration cards. Results: 87% of the patients who received heberprot-p treatment had a satisfactory outcome; of patients with unsatisfactory outcome the main complication was local infection (100%); 64,3% were males and 78,6% were older than 60 years, 64,3% had more than 10 years of diabetes and the most prevalent risk factors were hyperglycemia, overweight and obesity (or both), followed by dyslipidemia and depression, respectively. Conclusions: it was determined that local infection was the most frequent complication and hyperglycemia was the main risk factor.

Downloads

Download data is not yet available.

Author Biographies

Perla María Trujillo Pedrosa, Policlínico “Manuel Piti Fajardo”, Santo Domingo, Villa Clara

Especialista de I Grado en Medicina General Integral. Diplomada en Atención Integral al Pie Diabético. Profesora Asistente.

Maité George Arse, Policlínico “Manuel Piti Fajardo”, Santo Domingo, Villa Clara

Licenciada en Enfermería. Diplomada en Atención  Integral al Pie Diabético.

Justo Ricardo Ortega Sánchez, Policlínico “Manuel Piti Fajardo”, Santo Domingo, Villa Clara

Especialista de I Grado en Medicina Interna. Diplomado en Cardiología Hospitalaria. Profesor Instructor.

References

1. Torres HO. Diabetes mellitus. Tipos y etapas de esta enfermedad. Controlar su diabetes. La Habana: Científico-Técnica; 2007.

2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care [Internet]. 2012 [citado 2 Sept 2016];35 Suppl 1:S64-S71. Disponible en: http://care.diabetesjournals.org/content/35/Supplement_1/S64

3. Bustillo Solano EE, Bustillo Madrigal EE, Pérez Francisco Y, Pérez Sosa R, Brito García A, González Iglesia A, et al. Prevalencia de la diabetes mellitus y de la glucemia alterada en ayunas en un área de la ciudad de Sancti Spíritus. Rev Cubana Endocrinol [Internet]. 2013 [citado 2 Sept 2016];24(2):107-124. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532013000200002&lng=es&nrm=iso&tlng=es

4. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care [Internet]. 2012 [citado 2 Sept 2016];35(6):1364-1379. Disponible en: http://care.diabetesjournals.org/content/35/6/1364

5. García Herrera A, Rodríguez Fernández R, Peña Ruíz V, Rodríguez Hernández L, Acosta Cabadilla L, Febles Sanabria O, et al. El significado clínico del pie diabético en un análisis de diez años. Rev Cubana Ang Cir Vasc [Internet]. 2011 [citado 2 Sept 2016];12(1):[aprox.8 p.]. Disponible en: http://bvs.sld.cu/revistas/ang/vol12_01_11/ang08111.htm

6. Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Galán-Naranjo K, Ramírez-Navas M, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J [Internet]. 2009 [citado 12 Abr 2016];6(1):67-72. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/19291119

7. Rivero FE. Experiencias del Programa de atención integral a pacientes con pie diabético en el estado Zulia, Venezuela. Biotecnol Apl [Internet]. 2010 [citado 5 Oct 2016];27(2):[aprox. 14 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522010000200004

8. Inglés Maury NA, Pérez Inglés NA. Terapéutica ambulatoria con Heberprot-P en pacientes con úlceras de pie diabético. Rev Información Científica. 2014; 87(5).

9. Concepción DR, Álvarez Duarte H, Llanes Barrios JA, Valdés Pérez C, Franco Pérez N, Savigne Gutiérrez W. Conducta práctica y paradigmas quirúrgicos que ha modificado el Heberprot-P. Rev Cubana Ang Cir Vasc [Internet]. 2012 [citado 5 Oct 2016];13(2):[aprox. 7 p.]. Disponible en: http://bvs.sld.cu/revistas/ang/vol13_2_12/ang08212.htm

10. Rondón Bernard JE. Variables psicosociales implicadas en el mantenimiento y control de la diabetes mellitus: aspectos conceptuales, investigaciones y hallazgos. Revista Electrónica de Psicología de Iztacala [Internet]. 2011 [citado 5 Oct 2016];14(2):126-62. Disponible en: http://www.revistas.unam.mx/index.php/repi/article/view/26030

11. Osawa K, Miyoshi T, Koyama Y, Sato S, Akagi N, Morimitsu Y, et al. Differential association of visceral adipose tissue with coronary plaque characteristics in patients with and without diabetes mellitus. Cardiovas Diabetol [Internet]. 2014 [citado 17 Mar 2016];13:61. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24624968

12. Williams DT, Hilton JR, Harding KG. Diagnosing foot infection in diabetes. Clin Infect Dis. 2004;39 Suppl 2:S83-6.

13. González Benavides C, Pérez Mederos LM, Peraltas Pérez G. Resultados de la utilización del heberprot-P®. Acta Méd Centro [Internet]. 2014 [citado 7 Feb 2016];8(4):16-23. Disponible en: http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/192/257

14. Bakker K, Apelquist J, Schaper NC. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev [Internet]. 2012 [citado 7 Feb 2016];28(Suppl 1):225–231. Disponible en: http://iwgdf.org/wp-content/uploads/2013/03/1-dmrr2253-no-1.pdf

15. Raíces M. Resultados en Cuba del subprograma de atención integral al paciente con úlceras del pie diabético con el uso de Heberprot-P. Taller inicial. La Habana; 2016.

Downloads

How to Cite

1.
Trujillo Pedrosa PM, George Arse M, Ortega Sánchez JR. Complication that occurs in patients to heberprot-p treatment in a health area. Acta Méd Centro [Internet]. 2017 Apr. 3 [cited 2025 Jul. 7];11(2):44-52. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/827

Issue

Vol. 11 No. 2 (2017): April-June

Section

Original Articles

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).